Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    TMC310911
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC310911 75 mg twice daily;   Drug: TMC310911 150 mg twice daily;   Drug: TMC310911 300 mg twice daily;   Drug: TMC310911 300 mg once daily;   Drug: Ritonavir 100 mg twice daily;   Drug: Ritonavir 100 mg once daily
Phase: Phase 2
Sponsor: Tibotec Pharmaceuticals, Ireland
NCT Number: NCT00838162
Study Start: June 2009
Primary Completion: August 2009
2 Completed PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Condition: HIV-1
Intervention: Drug: TMC558445; TMC310911; Darunavir; Placebo
Phase: Phase 1
Sponsor: Tibotec Pharmaceuticals, Ireland
NCT Number: NCT00838760
Study Start: February 2009
Primary Completion: October 2009
3 Terminated PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Intervention: Drug: TMC589337, TMC589354, TMC310911, placebo
Phase: Phase 1
Sponsor: Tibotec Pharmaceuticals, Ireland
NCT Number: NCT00908414
Study Start: May 2009
Primary Completion: October 2009

Indicates status has not been verified in more than two years